Gadoteridol Dosage

Medically reviewed by Drugs.com. Last updated on Apr 9, 2024.

Usual Adult Dose for CNS Magnetic Resonance Imaging

Central Nervous System:
0.1 mmol/kg (0.2 mL/kg) administered as a rapid intravenous infusion (10 mL/min to 60 mL/min) or bolus (greater than 60 mL/min). In patients suspected of having poorly enhancing lesions, in the presence of negative or equivocal scans, a second dose of 0.2 mmol/kg (0.4 mL/kg) may be given up to 30 minutes after the first dose.

Extracranial and Extraspinal Tissues:
0.1 mmol/kg (0.2 mL/kg) administered as a rapid intravenous infusion (10 mL/min to 60 mL/min) or bolus (greater than 60 mL/min).

Usual Pediatric Dose for CNS Magnetic Resonance Imaging

Central Nervous System - to visualize lesions with abnormal vascularity in the brain (intracranial lesions), spine and associated tissues:
over 2 years of age:
0.1 mmol/kg (0.2 mL/kg) administered as a rapid intravenous infusion (10 mL/min to 60 mL/min) or bolus (greater than 60 mL/min).

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

US BOXED WARNING:

• NEPHROGENIC SYSTEMIC FIBROSIS (NSF): Gadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired elimination of the drugs. Use should be avoided in such patients unless the diagnostic information is essential and not available with noncontrasted MRI or other modalities. NSF may result in fatal or debilitating systemic fibrosis affecting the skin, muscle, and internal organs. The risk for NSF appears highest among patients with chronic, severe kidney disease (GFR less than 30 mL/min/1.73m2) or acute kidney injury. Patients should be screened for acute kidney injury and other conditions that may reduce renal function. For patients at risk for chronically reduced renal function (e.g., greater than 60 years, hypertension, or diabetes), estimate the GFR through laboratory testing. For patients at highest risk for NSF, do not exceed the recommended dose and allow a sufficient period of time for elimination of the drug from the body prior to re-administration.

Safety and efficacy have not been established in patients younger than 2 years; safety and efficacy of greater than 0.1 mmol/kg and sequential and/or repeat procedures have not been studied in pediatric patients.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

To ensure complete injection of the contrast medium, the injection should be followed by a 5 mL normal saline flush. The imaging procedure should be completed within 1 hour of the first injection of gadoteridol.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer